Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of P53 and Bcl-2

Pathology and Oncology Research

Volumn 10, Issue 3, 2004, Pages 154-158

  Amirghofran, Zahra ^a,b   Monabati, Ahmad ^a   Khezri, Abdolaziz ^a   Malek Hosseini, Zahra ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; bcl 2; p53; Transitional cell carcinoma of bladder

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER; PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TRANSITIONAL CELL CARCINOMA;

EID: 7044253464     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033744     Document Type: Article

References (28)

1. Hickman JA. Apoptosis and tumorigenesis. Curr Opin Genet Dev 12:67-72, 2002
2. Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 88:212-218, 2003
3. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 7:249-257, 2003
4. Batinac T, Gruber F, Lipozencic J et al. Protein p53 - structure, function, and possible therapeutic implications. Acta Dermatovenerol Croat 11:225-230, 2003
5. Laiho M, Latonen L. Cell cycle control, DNA damage checkpoints and cancer. Ann Med 35:391-397, 2003
6. Sherr CJ. Principles of tumor suppression. Cell 23; 116:235-246, 2004
7. Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL: Multivariate analysis of survival, recurrence, progression and development of metastasis in T1 and T2a transitional cell bladder carcinoma. Cancer 15; 94:1677-1684, 2002
8. Lin Z, Kim H, Park H, et al. The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium. Urol Res 31:272-275, 2003
9. Yu DS, Chang SY. The expression of oncoproteins in transitional cell carcinoma: its correlation with pathological behavior, cell cycle and drug resistance. Urol Int 69:46-50, 2002
10. Llopis J, Alcaraz A, Ribal MJ, et al. p53 expression predicts progression and poor survival in T1 bladder tumors. Eur Urol 37:644-653, 2000
11. World Health Organization. Histological typing of urinary bladder tumors. 10, 1973
12. Budd RC. Activation-induced cell death. Curr Opin Immunol 13:356-362, 2001
13. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 155:316-320, 1996
14. Korkolopoulou P, Konstantinidou AE, Christodoulou P, et al. Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: relation to cell cycle regulators and survival. Urology 1; 56:516-520, 2000
15. Roman S, Petrusca D, Moldovan I, et al. Evaluation of apoptosis of tumor and of apparently normal cells in human renal carcinoma. Immunol Lett 15; 67:15-22, 1999
16. Kong C, Zhang X, Takenaka I. Apoptotic cell death and Smad4 expression in transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 8:386-390, 2001
17. Zhang X, Kong C, Takenaka I. Evaluation of cell proliferation, apoptosis, and angiogenesis in transitional cell carcinoma of the renal pelvis and ureter. Urology 57:981-985, 2001
18. Townson JL, Naumov GN, Chambers AF. The role of apoptosis in tumor progression and metastasis. Curr Mol Med 3:631-642, 2003
19. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 36165-36175, 2003
20. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14:86-91, 2002
21. Lu QL, Abel P, Foster CS, Lalani EN. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 27:102-110, 1996
22. Uchida T, Minei S, Gao JP, et al. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol Rep 9:253-9, 2002
23. Ong F, Moonen LM, Gallee MP, et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 61:169-175, 2001
24. Asci R, Yildiz L, Sarikaya S, et al. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder. Urol Int 67:34-40, 2001
25. Kirsh EJ, Baunoch DA, Stadler WM. Expression of bcl-2 and bcl-X in bladder cancer. J Urol 159:1348-1353, 1998
26. Pfister C, Flaman JM, Dunet F, et al. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol 162:69-73, 1999
27. Harada H, Grant S. Apoptosis regulators. Rev Clin Exp Hematol 7:117-138, 2003
28. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 169: 1219-1228, 2003